Atara Biotherapeutics (ATRA) Cash & Equivalents (2013 - 2026)

Atara Biotherapeutics has reported Cash & Equivalents for 14 years, with the latest figure at $8.4 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 39.31% year-over-year to $8.4 million; the trailing twelve-month figure through Mar 2026 stood at $8.4 million (down 39.31% YoY), and the FY2025 full-year result was $8.5 million, down 66.04% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $8.4 million, down from $8.5 million in the prior quarter.
• The five-year high for Cash & Equivalents was $101.7 million in Q1 2022, with the low at $5.7 million in Q3 2025.
• Historically, Cash & Equivalents has averaged $41.6 million across 5 years, with a median of $35.1 million in 2024.
• Annual changes were most pronounced in 2023 — Cash & Equivalents dropped 0.5% — and 2025, when it sank 87.64%.
• Atara Biotherapeutics' Cash & Equivalents stood at $92.9 million in 2022, then plunged by 72.2% to $25.8 million in 2023, then dropped by 3.14% to $25.0 million in 2024, then sank by 66.04% to $8.5 million in 2025, then retreated by 1.18% to $8.4 million in 2026.
• The last three Cash & Equivalents figures came in at $8.4 million (Q1 2026), $8.5 million (Q4 2025), and $5.7 million (Q3 2025), per Business Quant data.